Cleveland BioLabs (CBLI) Poised to Capitalize Massively on Multiple Government Contracts for Radiation Countermeasures
Cleveland BioLabs, www.cbiolabs.com, is well-positioned as both a bio-defense and medical company, with proficiencies in radiation countermeasures, as well as preclinical cancer, stem cell and acute organ failure technologies. President and CEO of CBLI, Michael Fonstein, detailed excitement over CBLB502, the Company’s radiation countermeasure being favorably positioned to receive the final contract award by the DOD (pursuant to a Q1 FY10 Request For Proposal response). In an exclusive interview with BioMedReports, Fonstein revealed that the CBLB502 defense program is based on CBLI’s unique pharmacological approach of achieving radioprotectant (preventative) and radiation damage mitigation parameters via Protectans, molecules which shield the…